BACKGROUND/AIMS: The purpose of this study is to elucidate the efficacy and safety of combined peginterferon and ribavirin therapy in Korean patients with chronic HCV infection. METHODS: We retrospectively analyzed the clinical records of 84 patients. Thirty five patients with genotype 1 HCV infection were treated with peginterferon alpha-2a 180 microg/week and ribavirin 1,000-1,200 mg/day for 48 weeks, and 49 patients with genotype non-1 were treated with peginterferon alpha-2a 180 microg/week and ribavirin 800 mg/day for 24 weeks. RESULTS: An early virologic response was seen in 87.0% of patients with genotype 1 HCV. An end of treatment response (ETR) was seen in 82.6% and 97.6% of patients with genotype 1 and genotype non-1, respectively. An overall sustained virologic response (SVR) was seen in 53 patients (82.8%) of the 64 patients: in 16 (69.6%) of 23 patients with genotype 1 and in 37 (90.2%) of 41 patients with genotype non-1. An end of treatment biochemical response was seen in 58 patients (90.6%) [genotype 1, 20 patients (87.0%); genotype non-1, 38 patients (92.7%)], and a sustained biochemical response was achieved in 49 patients (76.6%) [genotype 1, 14 patients (60.9%); genotype non-1, 35 patients (85.4%)]. Independent factors affecting an SVR were HCV genotype and the baseline HCV RNA level. CONCLUSIONS: This study shows that a combination therapy of peginterferon and ribavirin is highly effective for chronic HCV infection, producing a high SVR and ETR.
BACKGROUND/AIMS: The purpose of this study is to elucidate the efficacy and safety of combined peginterferon and ribavirin therapy in Korean patients with chronic HCV infection. METHODS: We retrospectively analyzed the clinical records of 84 patients. Thirty five patients with genotype 1 HCV infection were treated with peginterferon alpha-2a 180 microg/week and ribavirin 1,000-1,200 mg/day for 48 weeks, and 49 patients with genotype non-1 were treated with peginterferon alpha-2a 180 microg/week and ribavirin 800 mg/day for 24 weeks. RESULTS: An early virologic response was seen in 87.0% of patients with genotype 1 HCV. An end of treatment response (ETR) was seen in 82.6% and 97.6% of patients with genotype 1 and genotype non-1, respectively. An overall sustained virologic response (SVR) was seen in 53 patients (82.8%) of the 64 patients: in 16 (69.6%) of 23 patients with genotype 1 and in 37 (90.2%) of 41 patients with genotype non-1. An end of treatment biochemical response was seen in 58 patients (90.6%) [genotype 1, 20 patients (87.0%); genotype non-1, 38 patients (92.7%)], and a sustained biochemical response was achieved in 49 patients (76.6%) [genotype 1, 14 patients (60.9%); genotype non-1, 35 patients (85.4%)]. Independent factors affecting an SVR were HCV genotype and the baseline HCV RNA level. CONCLUSIONS: This study shows that a combination therapy of peginterferon and ribavirin is highly effective for chronic HCV infection, producing a high SVR and ETR.
Authors: Chansoo Moon; Kyu Sik Jung; Do Young Kim; Oidov Baatarkhuu; Jun Yong Park; Beom Kyung Kim; Seung Up Kim; Sang Hoon Ahn; Kwang-Hyub Han Journal: Dig Dis Sci Date: 2014-09-19 Impact factor: 3.199
Authors: Sang Hoon Park; Choong Kee Park; Jin Woo Lee; Young Seok Kim; Sook-Hyang Jeong; Yun Soo Kim; Ju Hyun Kim; Seong Gyu Hwang; Kyu Sung Rim; Hyung Joon Yim; Jae Youn Cheong; Sung Won Cho; June Sung Lee; Young Min Park; Jeong Won Jang; Chun Kyon Lee; Joo Hyun Shon; Jin Mo Yang; Young Soo Ju Journal: Gut Liver Date: 2012-01-12 Impact factor: 4.519
Authors: Yu Jin Kim; Jin Woo Lee; Yun Soo Kim; Sook Hyang Jeong; Young Seok Kim; Hyung Joon Yim; Bo Hyun Kim; Chun Kyon Lee; Choong Kee Park; Sang Hoon Park Journal: Korean J Hepatol Date: 2011-09
Authors: Hyun Seok Lee; Young Oh Kweon; Won Young Tak; Soo Young Park; Eun Jung Kang; Yu Lim Lee; Hae Min Yang; Hyun Woo Park Journal: Clin Mol Hepatol Date: 2013-06-27
Authors: Byung Chul You; Young Seok Kim; Hun il Kim; Se Hun Kim; Seung Sik Park; Yu Ri Seo; Sang Gyune Kim; Se Whan Lee; Hong Soo Kim; Soung Won Jeong; Jae Young Jang; Boo Sung Kim Journal: Clin Mol Hepatol Date: 2012-09-25